Evidence map›Paper›PMID 29872959›Full record

ArticleStem cell reviews and reports2018

Role of Telomeric TRF2 in Orosphere Formation and CSC Phenotype Maintenance Through Efficient DNA Repair Pathway and its Correlation with Recurrence in OSCC.

Arka Saha, Souvick Roy, Madhabananda Kar, Shomereeta Roy, Shweta Thakur, SwatiShree Padhi, Yusuf Akhter, Birendranath Banerjee

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Telomere Reprogramming and Cellular Metabolism: Is There a Link?International journal of molecular sciences · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Telomere-related Markers for Cancer.Current topics in medicinal chemistry · 2020
    Review
  10. The roles of glucose metabolic reprogramming in chemo- and radio-resistance.Journal of experimental & clinical cancer research : CR · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Arka SahaMolecular Stress and Stem Cell Biology Group, KIIT School of Biotechnology, Disease Biology Lab, KIIT University, Bhubaneswar, Odisha, 751024, India.
Souvick RoyMolecular Stress and Stem Cell Biology Group, KIIT School of Biotechnology, Disease Biology Lab, KIIT University, Bhubaneswar, Odisha, 751024, India.
Madhabananda KarDepartment of Surgical Oncology, All India Institute of Medical Sciences, (AIIMS), Bhubaneswar, Odisha, 751019, India.
Shomereeta RoyMolecular Stress and Stem Cell Biology Group, KIIT School of Biotechnology, Disease Biology Lab, KIIT University, Bhubaneswar, Odisha, 751024, India.
Shweta ThakurCentre for Computational Biology and Bioinformatics, School of Life Sciences, Central University of Himachal Pradesh, Shahpur, Himachal Pradesh, 176206, India.
SwatiShree PadhiMolecular Stress and Stem Cell Biology Group, KIIT School of Biotechnology, Disease Biology Lab, KIIT University, Bhubaneswar, Odisha, 751024, India.
Yusuf AkhterDepartment of Biotechnology, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow, Uttar Pradesh, 226025, India.
Birendranath BanerjeeMolecular Stress and Stem Cell Biology Group, KIIT School of Biotechnology, Disease Biology Lab, KIIT University, Bhubaneswar, Odisha, 751024, India. bnbanerjee@kiitbiotech.ac.in.ORCID 0000-0001-8819-8231
KIIT University · INAll India Institute of Medical Sciences Bhubaneswar · INBabasaheb Bhimrao Ambedkar University · INCentral University of Himachal Pradesh · IN

Funding

Board of Research in Nuclear Sciences (IN) 2013/35/45/BRNSDepartment of Biotechnology , Ministry of Science and Technology BT/PR/14659/MED/31/108/2010
6 · The paper itself

Abstract

The major problem to effective treatment of oral cancer is the presence of therapy resistance. Presence of cancer stem cell in the bulk of tumor have been implicated in therapeutic resistance. In this study, we report a non-telomeric role of TRF2 in formation of oral cancer spheroids and CSC phenotype maintenance via an efficient DNA damage repair mechanism in the presence of chemotherapeutic insult. We report reduced sphere formation efficiency and reduced spheroid size in TRF2 silenced oral cancer cell lines. TRF2 silenced orospheres further reported reduced proliferative capacity as compared to non-silenced orospheres. Furthermore, TRF2 silencing hampered the migratory potential of oral cancer cell line and also reduced the expression of several CSC markers like CD44, Oct4, Sox2, KLF4 and c-Myc along with β-catenin and hTERT molecules both in Cal27 cell line and generated orospheres. TRF2 silencing impaired efficient DNA damage repair capacity of non-orospheric and orospheric cells and repressed ERCC1 expression levels when treated with Cisplatin. TRF2 overexpression was also observed to correlate with poor overall survival and disease relapse of OSCC patients. In silico studies further identified several amino acid residues that show high binding affinity and strong protein-protein interactions among TRF2 and CSC marker KLF4. Hence, our report confirms a non-telomeric role of TRF2 in spheroid generation, maintenance of CSC phenotype and efficient DNA damage repair capacity contributing to chemotherapy resistance in oral cancer cell line. We further iterate the use of TRF2 as a prognostic marker in OSCC for faster detection and improved survival.

Indexed as

DNA RepairBiomarkers, TumorCarcinoma, Squamous CellCell Line, TumorCell MovementCell ProliferationCisplatinComputer SimulationDown-RegulationFemaleGene SilencingHumansKruppel-Like Factor 4MaleMiddle AgedMouth NeoplasmsBiomarkers, TumorCisplatinKLF4 protein, humanKruppel-Like Factor 4TelomeraseTelomeric Repeat Binding Protein 2CSC maintenanceDDROrospheresOSCCPrognosis and recurrenceTRF2

Identifiers

PMID29872959
OpenAlexW2806884836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.